Trading Signals: HTBX Stock Price Prediction and Forecast (Mon. Dec. 28, 2015 - Mon. May. 2, 2022)(Heat Biologics, Inc.)
| HTBX latest price $9.0300 (-5.84%) ($9.0300 - $9.0300) on Mon. Feb. 22, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 8.77% (three month average) | RSI | 66 | Latest Price | $9.0300(-5.84%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | HTBX declines -4.7% a day on average for past five trading days. | Weekly Trend | HTBX advances 11.1% a week on average for past two weeks. | Market Behavior | Rotation from growth to value for large cap. Rotation from growth to value for small cap. | Correlated ETFs | Broad market will support HTBX advance at 0% a week (0% probability) ARKG(42%) XBI(41%) ARKK(37%) ACES(36%) IBB(36%) | Factors Impacting HTBX price | HTBX will decline at least -4.385% in a week (0% probabilities). VIXM(-25%) VXX(-21%) UUP(-15%) IGOV(-11%) XLU(-5%) | | | | | Relative Volatility | | | | Market Trend Strength | -4.385% (StdDev 8.77%) | Hourly BBV | -2.1 () | Intraday Trend | 0% | | | |
|
5 Day Moving Average | $9.74(-7.29%) | 10 Day Moving Average | $10.33(-12.58%) | 20 Day Moving Average | $9.01(0.22%) | To recent high | -28% | To recent low | 71.7% | Market Cap | $994m | | | | Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC. |